thesi updat despit post one best quarter
time confer call interestingli focus
potenti modest neg build us
miss forest tree ye possibl fx
tariff clip ep growth slightli howev
context econom strength current see
growth rate impli share gain balanc sheet
pois deliv notabl upsid continu see
stori compel relat core growth ye see
slow tougher comp gradual
stimulu strong us econom activ drive
upsid well like suggest soft land
vs dip lsd organ term ep forecast
tweak higher forecast reiter
rais ep nickel overal move
core forecast margin move touch lower fx
large-scal push tax rate
tweak pt move impli double-digit
upsid lower due higher rate assumpt
dcf buyer also like share
post print
read tool posit growth outperform
across complex like
read dx neutral trend remain consist price
tick lower sequenti modest headwind
read dental neg trend materi
wors also much better stock ralli
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
platform grew msd led life
management remain confid overal macro demand
environ busi geographi well
part
china biopharma continu lead geograph end
market growth show littl sign slow
fx hw bp om like continu hw
dx face constant price pressur due stiff competit
new account
tweak vs prior msd vs st
rais ep vs prior
st
initi ep w/ core revenue
revenue om
margin declin due lower sale volum currenc
impact strengthen usd invest spend
growth tradtl consum equip
due inventori adj na distribut channel modest
declin europ japan
remain encourag market stabil na
sell-out data posit
continu invest spark
clear align offer take time make
meaning impact strong opp
spin-off track
om core
beckman hsd w/ posit result across product
sciex hsd led na china strength across pharma
food test end mkt driven recent launch
achiev annual
cost save target
reinvest cost save sale
doubl annual revenue new product
increas market visibl
dx core om driven
weaken high-growth market currenc usd
beckman core lsd w/ strength china
partial off-set soft dev mkt
growth driven immunoassay
strength autom
cost save lab
dxa launch drive meaning
benefit new product launch
om core
chines government focu water qualiti tw
drive growth region
solid momentum industri muni end
mkt us europ
commerci execut drive
chemtreat msd sequenti driven demand
trojan hsd w/ demand across muni na
broad-based growth across develop led
ls strong na china
biopharma dd
mid-teen pall
sciex strength led biopharma china china
dental weak europ particularli germani
disrupt japan due weather
dont believ germani problem
industri strength driven metal mine off-set
 driven water qualiti demand particularli due
polici chang surfac water
china tariff primari concern
previous believ impact w/
increment tariff
chain manufactur reorgan well
caution regard deriv impact
see strong growth china
currenc ebit margin
impact exclud currenc
strength dollar particularli high growth
wouldv bp
market w/ fair amount revenu low cost base
exacerb transact item
transact side swing brazil turkey
argentina mark market receiv
take fx hit
theyv got coupl qs bleed
strong capac
anticip gener year
paid w/
anticip achiev leverag
end year
rise rate help w/
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin octob
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
